Compass Pathways
在场
Compass Pathways 是一家在股票代码 CMPS (GB) 下上市的公司。
高管
查看带有其 26 名主要高管的组织结构图
Compass Pathways 搜索最多的简介
高管在Compass Pathways变化
- David Norton 曾任 Lead Director, 现升职为 Interim Chairman of the Board (新闻发布的2024三月30号).
- Ekaterina Malievskaia, Director, 已经离开公司 (新闻发布的2024三月30号).
- George Goldsmith, Executive Chairman, 已经离开公司 (新闻发布的2024三月30号).
创建提醒
跟踪 Compass Pathways 的高管变动
生物技术
Compass Pathways 拥有 2,289 家竞争者，其中包括 Lonza (瑞士)、Eurofins (卢森堡) 和 Adaptive Phage Therapeutics (美国(美洲))。
Popular M&A news in 生物技术
- Delphia Therapeutics 刚刚宣布为 67 筹款数百万美元。 (公布2024五月7号).
- Karius 刚刚宣布为 100 筹款数百万美元。 (公布2024五月3号).
- Transcarent 刚刚宣布为 126 筹款数百万美元。 (公布2024五月2号).
生物技术 行业的其他推荐联系人
消息
Compass Pathways 的最新新闻稿
- Study results of psilocybin treatment in bipolar II depression published in JAMA Psychiatry | Compass Pathways
- Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment-resistant depression, and launches new research center | Compass Pathways
- Mental Health Care News, Articles & Stories from Compass Pathways
- Mental Health Care News, Articles & Stories from Compass Pathways
- COMPASS Pathways announces publication of first study evaluating potential of AI model to predict outcomes of COMP360 psilocybin treatment in treatment-resistant depression | COMPASS Pathways
- COMP360 psilocybin treatment in TRD with antidepressants | COMPASS Pathways
- COMPASS Pathways announces publication of positive data from treatment-resistant depression phase 2 clinical trial of COMP360 psilocybin alongside antidepressants in Nature journal, Neuropsychopharmacology | COMPASS Pathways
- Data demonstrating long-term improvement in depression in cancer patients following single dose of COMP360 psilocybin therapy to be presented at ASCO 2023 | COMPASS Pathways
- Mental Health Care News, Articles & Stories from Compass Pathways
- Mental Health Care News, Articles & Stories from Compass Pathways
- View more press releases Close
关于 Compass Pathways 的社交媒体
保持联系
通过电子邮件联系联系该企业高管，包括 Kabir Nath 
